Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals recently announced its largest-ever acquisition.
Read the full articleYou might also wanna read
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine disease specialist Crinetics Pharmaceuticals. The
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies
Vertex’s Crinetics Deal Balances Growth with Integration Risk
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipel
Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals
Related Stocks: VRTX
Comments
Sign in to join the conversation.
No comments yet. Be the first.